Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
MDXH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $3.71
Previous CloseN/A
Volume27.23K
Average Volume (3M)120.16K
Market Cap
$179.18M
Enterprise Value$160.59M
Total Cash (Recent Filing)$65.67M
Total Debt (Recent Filing)$83.98M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 12, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding49,497,334
10 Day Avg. Volume162,147
30 Day Avg. Volume120,157
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue2.30
Enterprise Value/Gross Profit3.73
Enterprise Value/Ebitda-14.58
Forecast
1Y Price Target
$5.80Price Target Upside61.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement expressed confidence in reaching adjusted EBITDA break-even in the second quarter.
Revenue GrowthMomentum across the portfolio continues with total revenue growing 20% Y/Y with both liquid and tissue volumes strong.
Strategic AcquisitionThe acquisition of the ExoDx Prostate test is seen as strategically fitting well with MDx's offerings and having a better product/market fit.
Bears Say
Market ValuationShares of MDXH trade at just 0.8x our 2026 rev estimate of $128M, below small cap peers at 2.0x, and MDXH is primed to achieve multiple expansion.
Price TargetThe price target was adjusted from $7.00 to $5.00, indicating a more conservative outlook.
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $1.35 and its highest was $3.71 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $179.18M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Aug 05, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.123 by -$0.027.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.11.
How many shares outstanding does MDxHealth have?
MDxHealth has 49,497,334 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.123. Following the earnings report the stock price went up 10.442%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
MDxHealth Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (61.56% Upside)
$5.80 (61.56% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.4%
Last 30 Days ▲ 18.6%
Last 30 Days ▲ 18.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.52%
12-Months-Change
Fundamentals
Return on Equity
-1552.23%
Trailing 12-Months
Asset Growth
7.47%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for MDxHealth reflected strong revenue growth and operational performance, particularly in the tissue-based test segment, with the company maintaining a strong financial position. However, there was an increase in net loss due to non-cash adjustments, and growth in the liquid-based tests segment was less impressive. Overall, the company demonstrated significant positive trends, particularly in revenue and profitability outlooks.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$5.80
▲(61.56% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.09% Mutual Funds
41.63% Other Institutional Investors
58.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---